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Background: Various interventions have been tested as primary prevention of colorectal can-
cers (CRC), but comprehensive evidence comparing them is absent. We examined the effects 
of various chemopreventive agents (CPAs) on CRC incidence and mortality.
Methods: We did a network meta-analysis based on a systematic review of randomized con-
trolled trials (RCTs) that compared at least one CPA (aspirin, antioxidants, folic acid, vitamin 
B6, vitamin B12, calcium, vitamin D, alone or in combination) to placebo or other CPA in 
persons without history of CRC. Several databases were searched from inception up to March 
2017. Primary outcomes were early and long-term CRC incidence and mortality.
Results: Twenty-one RCTs comprising 281,063 participants, 9 RCTS comprising 160,101 partici-
pants, and 7 RCTs comprising 24,001 participants were included in the network meta-analysis for 
early risk of CRC incidence, long-term risk of CRC incidence and mortality, respectively. For early 
CRC incidence, no CPAs were found to be effective. For long-term CRC incidence and mortality, 
aspirin was the only intervention that showed protective effects with potential dose-dependent effects 
(risk ratio [RR], 0.74 [95% CI, 0.57–0.97] for high-dose [≥325 mg/day] and RR, 0.81 [95% CI, 
0.67–0.98] for very-low-dose [≤100 mg/day]). Similar trend was found for  mortality (RR, 0.43 
[95% CI, 0.23–0.81] for low-dose [>100–325 mg/day] and RR, 0.65 [95% CI, 0.45–0.94] for very-
low-dose). However, in net clinical benefit analysis, when combining risk estimates on mortality 
from CRC, cardiovascular disease, and pooled risk estimates of major gastrointestinal bleeding, 
low-dose aspirin provided the highest net survival gain (%) of 1.736 [95% CI, 1.010–2.434].
Conclusion: Aspirin at the dose range of 75–325 mg/day is a safe and effective primary pre-
vention for long-term CRC among people at average risk. None of the other CPAs were found 
to be effective. There may potentially be differential effects among various doses of aspirin that 
needs further investigation.
Keywords: colorectal cancer, primary chemoprevention, chemopreventive agents, aspirin, 
network meta-analysis, net clinical benefit analysis
Plain language summary
Aspirin (75–325 mg/day) is a safe and effective intervention to prevent colorectal cancer among 
people at average risk. The effect may be dose and time-dependent. No other tested interventions 
were found to be effective. Net clinical benefit analysis combining mortality from CRC, cardio-
vascular disease, and bleeding indicated that low-dose aspirin (>100–325 mg/day) provided the 
highest net survival gain. For patients with low risk of bleeding, low-dose aspirin may slightly 
be more attractive due to a larger reduction in CRC mortality and the best net clinical benefit. 
For patients at high risk of bleeding, very-low-dose aspirin (≤100 mg/day) may be more appro-
priate due to its best safety profile especially in cases of GI bleeding. There may potentially be 
differential effects among various doses of aspirin that needs further investigation.
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Introduction
Colorectal cancer (CRC) is the fourth leading cause of death 
due to cancer worldwide.1 The burden of CRC on society 
with respect to mortality, morbidity, and costs is enormous. 
Therefore, prevention of CRC is an important public health 
objective. A number of pharmacological interventions have 
been investigated in randomized controlled trials (RCTs)2–32 
as chemopreventive agents (CPAs) for CRC in persons at 
average risk (those without personal or family history of 
colorectal neoplasia or conditions such as inflammatory 
bowel disease or hereditary colorectal cancer syndrome)33 
with variable results. A recent meta-analysis of RCTs by the 
United States Preventive Services Task Force (USPSTF) sug-
gested that aspirin taken for several years could be effective in 
reducing long-term incidence and mortality due to CRC.34,35 
However, the relative efficacy and safety of aspirin at different 
doses has not been investigated yet. Moreover, comprehen-
sive evidence comparing different CPAs including aspirin 
is still lacking. Previous reviews and meta-analyses27,34,36–40 
have focused only on pair-wise comparison of various CPAs.
Hence, we performed a systematic review and network 
meta-analysis (NMA) to determine the relative efficacy and 
safety of various CPAs on CRC incidence and mortality in per-
sons at average risk. Since aspirin is recommended by USPSTF 
for both prevention of cardiovascular disease and colorectal 
cancer,35 therefore interested to evaluate the overall impact 
of various doses of aspirin on CRC mortality, cardiovascular 
(CV) mortality, and major gastrointestinal (GI) bleeding events 
through net clinical benefit analysis. This information may 
uniquely offer an evaluation to the multidimensional impact 
of a single intervention, which is aspirin in this case.
Methods
Protocol and registration
This study was performed as part of a systematic review 
which has been previously registered (PROSPERO 
CRD42015025849)41 and was reported according to the 
Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) extension statement for NMA.42
Search strategy and study selection
We identified relevant studies by a systematic search of Med-
line, Embase, Cochrane Central Register of Controlled Trials, 
CINAHL Plus, and International Pharmaceutical Abstracts 
until March 2017. In addition, we searched the clinical trial 
registry (www.clinicaltrials.gov) and published systematic 
reviews. The search was restricted to studies published from 
2008 onwards because studies published up to 2007 could 
be identified from the published high-quality systematic 
reviews.36,37,39 Studies included were RCTs and long-term 
follow-up of RCTs, which reported the efficacy of any CPAs 
for the primary prevention of CRC in individuals at average 
risk.33 Supplement 1 details the search strategies.
Type of interventions
Candidate CPAs were aspirin, any antioxidants (vitamins A, 
C and E, beta-carotene and selenium alone or in different 
combinations), folic acid, vitamin B6, vitamin B12, calcium 
and vitamin D (alone or in combination). The interventions 
included are those which have been investigated as CPAs 
for primary prevention of CRC. Comparators were another 
candidate CPA or placebo. We classified aspirin (ASA) into 
three groups for the analysis as described by the latest review 
for the USPSTF34: high-dose or HDASA (>325 mg/day), low-
dose or LDASA (>100 and ≤325 mg/day), and very-low-dose 
or VLDASA (≤100 mg/day) aspirin.
Outcomes of interest
Primary efficacy outcomes of interest were incidence and 
mortality due to CRC. We present primary efficacy out-
comes stratified by follow-up period after initiation of CPA 
as early risk (0–10 years) and long-term risk (0–≥20 years) 
since previous data showed that timing of intervention might 
impact outcomes.34 For safety outcomes, we collected data 
for interventions with evidence of efficacy in reducing either 
long-term CRC incidence or mortality (that is aspirin at dif-
ferent doses). Safety outcomes of interest were CV mortal-
ity and major GI bleeding events. The study investigators 
defined GI bleeding events  that required hospitalization, 
transfusion, leading to death,  as fatal or major. They also 
defined CV mortality as deaths due to any CV complications 
including myocardial infarction (MI), stroke (ischemic and 
hemorrhagic) or CV deaths (excluding deaths due to GI 
bleeding events).
Data extraction and quality assessment
Description of data extraction is reported in Supplement 2. 
Data were extracted independently by two reviewers (S.K.V, 
S.M.C). The most recent data were included if multiple pub-
lications of the same trial were retrieved. The study authors 
were contacted if required data were not available from pub-
lications. (Table S2.1 in Supplement 2). For all outcomes, we 
used the initial number of participants randomized to each 
trial arm and performed the analyses irrespective of how the 
authors of the original trials had analyzed the data (intention-
to-treat principle).43 Participants who were lost to follow-up 
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were considered survivors, free of CRC or adverse events. 
Two reviewers (S.K.V, K.G.L) independently assessed the risk 
of bias (ROB) using the revised Cochrane risk of bias tool 
(RoB 2.0).44 Any discrepancies were resolved by consensus. 
The quality of evidence from NMA was evaluated using 
GRADEpro® GDT software online.45 Description of grading 
of evidence is provided in Methods S2.1 in Supplement 2.
Data synthesis and statistical analysis
A more detailed description of data synthesis and statisti-
cal analysis is provided in Methods S2.1 and Table S2.2 
in Supplement 2. The relative intervention effects (ie, risk 
ratio [RR]) were estimated for individual studies. A direct 
meta-analysis was used to pool RRs using a random-effects 
model. Heterogeneity was assessed using the Cochran Q 
test and the I² statistic. A random-effects NMA using con-
sistency model was applied to compare all interventions 
using direct and indirect data.46,47 Inconsistency assumption 
was evaluated using the global inconsistency test by fitting 
design-by-treatment in the inconsistency model. Placebo was 
used as the common comparator in the network model. In 
the network meta-analysis, the surface under the cumulative 
ranking (SUCRA) curves were estimated to rank the inter-
vention hierarchy. Higher SUCRA scores (ranging from 0 
to 1) correspond to a higher ranking for prevention of CRC 
incidence and mortality and lower SUCRA scores correspond 
to a higher ranking for safety regarding  CV mortality and GI 
bleeding events, compared with other CPAs. Publication bias 
was examined with a comparison-adjusted funnel plot.48 For 
statistical analysis, we used Stata version 14.0 (StataCorp, 
College Station, TX, USA). To assess the robustness of our 
primary efficacy outcomes, multiple pre-specified sensitivity 
analyses were performed by restricting studies with low-risk 
of bias, follow-up period of 0−≥20 years after CPA initiation 
and various other assumptions (Table S2.3 in Supplement 2).
Net clinical benefit (NCB) analysis
Similar to approaches used in previous meta-analyses,53,54 an 
NCB analysis was performed to assess the balance of benefits 
from CRC mortality prevention34 and CV benefits49,50 with 
other risks51,52 of aspirin at different doses. Detailed description 
of NCB analysis is presented in Methods S2.2 in Supplement 
2. Net survival gain (a way to represent the results of NCB) 
was calculatd by reviewing the estimated absolute effect of 
aspirin on long-term CRC mortality and CV mortality (the data 
for CV mortality comprised of mortality due to myocardial 
infarction [MI], stroke [ischemic and hemorrhagic], and other 
CV events apart from GI bleeding events) and subtracted the 
risk of mortality due to major GI bleeding events. With this 
approach, GI bleeding and hemorrhagic stroke associated with 
aspirin were comprehensively integrated into the equation. The 
NCB was calculated according to the formula, Net survival 
gain (%)= Difference in pooled risk estimates of CRC mortality 
between reference and intervention + Difference in pooled risk 
estimates of CV mortality between reference and interven-
tion − Weight x difference in pooled risk estimates of major 
GI bleeding events between reference and intervention. For 
interpretation, a higher value of net survival gain corresponds 
to the more benefit gain for CPAs compared with the placebo. 
The weighting factor was determined by the proportion of 
death among patients with GI bleeding. Based on previously 
published reports (Methods S2.2), fatal GI bleeding event had 
approximately 6% of the effect of single mortality; therefore 
a weighting factor of 0.06 was used. Additional sensitivity 
analyses of NCB were conducted by varying weighting factors 
from 0.01 to 0.16 (Methods S2.2). The scatter plot between 
combined risk estimates of mortality from CRC and CV and 
pooled risk estimates of major GI bleeding was also produced 
to demonstrate the risk vs. benefit. Pooled risk estimate of 
the treatment with reference was calculated based on meta-
analyses.55 To obtain the 95% confidence intervals of NCB, 
1,000 bootstrap samples of risk estimates were performed 
for each intervention to calculate the risk differences among 
groups receiving placebo and various doses of aspirin.56,57 A 
series of threshold analyses were also performed by varying 
the weight for the case-fatality ratio of GI bleeding and by 
varying the incidence of GI bleeding to evaluate the impact 
of varying risks of GI bleeding on the NCB.
For NCB analysis, we collected data on CV mortality 
and major GI bleeding events from fair and good quality 
(criteria defined by the USPSTF)58 primary and secondary 
cardiovascular disease (CVD) prevention trials on aspirin in 
average-risk individuals for CRC as recently reported by the 
updated USPSTF reports.52
Results
Study selection
A PRISMA flow diagram depicting the search and selection 
process for the primary outcomes is presented in Figure S1.1 
in Supplement 1. Our search identified a total of 4,573 cita-
tions after exclusion of duplicates. Among the 145 articles 
assessed for full text, 112 studies were excluded with reasons. 
In total, 21 RCTs2–7,9–13,15–25 reporting the early risk of CRC 
incidence and 12 RCTs8,24–31,59–64 reporting the long-term 
risk of either CRC incidence or mortality were included 
in our analysis. Another study65 reporting the early risk of 
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CRC incidence was identified, but excluded with reasons 
( Supplement 2). Data on long-term risk of either CRC inci-
dence or mortality from these 12 studies were identified from 
six post-trial observational studies8,28–31,59 and two individual 
participant data (IPD) meta-analyses.26,27 Additional unpub-
lished relevant information were obtained from the authors of 
the Women Health Study (WHS), the Women’s Antioxidant 
Cardiovascular Study (WACS), the Women’s Antioxidant and 
Folic Acid Cardiovascular Study (WAFACS) and Physicians’ 
Health Study II and used these data in the analysis of early 
risk of CRC incidence (Table S2.1 Supplement 2).
For safety outcomes, we collected data from 24 RCTs 
(including 6 RCTs reporting either the long-term risk of CRC 
incidence and mortality) on aspirin included in the updated 
USPSTF review52 (Figure S3.1 in Supplement 3). Safety 
data from an additional trial (Dutch transient ischemic attack 
trial.; DTIA),64 which reported long-term CRC mortality, 
was also included.
Characteristics of the included studies
Table 1 describes the characteristics of all included studies 
(a more detailed description is provided in Tables S3.1–S3.12 
in Supplement 3). In total, 21 RCTs2–7,9–13,15–25,32 with 281,063 
participants comparing 13 CPAs (Figure 1) were included in 
the NMA of early risk of CRC. Mean age of the population 
was 61 years. The length of follow-up from recruitment to 
study was 3.4–10 years.
Among 12 RCTs reporting the long-term risk of CRC, 9 
RCTs8,24,25,28,30,31,59–61 comparing 9 interventions with 160,101 
participants (Figure 2A) treated for 3.2–10 years were 
included in the NMA of the long-term CRC incidence. Seven 
RCTs24,25,60–64 comparing seven interventions (Figure 2B) with 
24,001 participants treated for approximately 2.6–10 years were 
included in the NMA of the long-term CRC mortality. Duration 
of follow-up among these 12 trials ranged from around six to 
more than 20 years. Mean age of the population was 60 years. 
All trials with long-term follow-up data were double-blinded 
and placebo-controlled, except one (open control design).24
Safety outcomes for aspirin at different doses were avail-
able from 25 RCTs (Tables S3.9, S3.10 in Supplement 3), 
including 11 primary and 14 secondary CVD prevention trials 
in average-risk individuals for CRC with an average follow-
up of 1–10 years. Characteristics of all studies reporting 
safety outcomes are prsented in Table S3.10 in Supplement 3.
Quality of included studies
A detailed description of the risk of bias (ROB) assessment 
among included RCTs are presented in Tables S3.4 and S3.8 
in Supplement 3. Among 21 RCTs reporting early risk of 
CRC (Table S3.4), 17 trials4–7,9,10,12,15,16,18–23 had low ROB in 
most criteria. The remaining four trials were judged to be at 
high ROB.2,13,16,17 Among 12 RCTs reporting the long-term 
risk of CRC (Table S3.8), no studies were judged to be at high 
risk of bias in any domain. For safety outcomes analyses, we 
included only fair-to-good quality RCTs (as per the criteria 
defined by USPSTF58 from the updated USPSTF review.52)
Effects on the primary efficacy outcomes
Treatment effects estimated from pairwise meta-analysis are 
presented in Supplement 4, without evidence of any substan-
tial statistical heterogeneity. Treatment effects estimated from 
NMA for CPAs on early, long-term CRC incidence, and mor-
tality are presented in Supplements 5, 6 and 7, respectively.
Early risk of CRC incidence
Based on the NMA, there was no effect on the early risk of 
CRC incidence within approximately 3.4–10 years of initia-
tion of HDASA (RR, 0.91 [95% CI 0.55–1.53]), LDASA 
(RR, 1.15 [95% CI 0.75–1.74]), VLDASA (RR, 0.89 [95% 
CI 0.63–1.26]), antioxidants alone (RR, 0.94 [95% CI 0.81–
1.10]) or with ASAVLD (RR, 0.97 [95% CI 0.69–1.37]), folic 
acid alone (RR, 1.00 [95% CI 0.14–7.14]) or with vitamin B12 
(RR, 0.94 [95% CI 0.66–1.35]) or with vitamin B12 and B6 
(RR, 1.17 [95% CI 0.81–1.70]), calcium (RR, 0.19 [95% CI 
0.01–3.60]), and vitamin D (RR, 1.03 [95% CI 0.59–1.82]), 
compared to placebo (Table S5.1 in Supplement 5). The 
results of NMA were similar to those obtained using standard 
pairwise meta-analysis and robust to the changes in sensitiv-
ity analyses (Figure S5.3 and Table S5.2 in Supplement 5).
Long-term risk of CRC incidence
NMA based on seven studies,8,24,25,28,30,31,59 for which the long-
term incidence of CRC with a follow-up of more than 10 
years suggested that, compared with placebo, HDASA (RR, 
0.74 [95% CI 0.57–0.97]) was ranked best for reducing the 
long-term CRC incidence, followed by VLDASA (RR, 0.81 
[95% CI 0.67–0.98]), calcium with vitamin D (RR, 0.96 [95% 
CI 0.81–1.13]), LDASA (RR, 1.03 [95% CI 0.83–1.27]), and 
any antioxidants (RR, 1.07 [95% CI 0.89–1.28]) (Table S6.1 
in Supplement 6). This is consistent with the pairwise meta-
analysis (Figure S6.3 in Supplement 6). When we assessed 
comparative efficacy among aspirin at different doses, none of 
the treatments were superior over others (Figure 3). Overall, 
the results were robust to the changes in sensitivity analyses 
and HDASA, and VLDASA remained superior to placebo 
(Table S6.2 in Supplement 6).
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Long-term risk of CRC mortality
NMA based on 5 RCTs24,25,62–64 with follow-up of more than 
10 years suggested that, compared with placebo, LDASA 
(RR, 0.43 [95% CI 0.23–0.81]) was ranked best for reduc-
ing long-term mortality due to CRC, followed by VLDASA 
(RR, 0.65 [95% CI 0.45, 0.94]) and HDASA (RR, 0.71 
[0.50–1.01]), respectively (Table S7.1 in Supplement 7). 
NMA results were consistent with the pairwise meta-analysis, 
except for LDASA (Figure S7.3 in Supplement 7). When 
we assessed comparative efficacy, LDASA was not superior 
to VLDASA (RR, 0.65 [95% CI 0.34–1.25]) and HDASA 
(RR, 1.66 [95% CI 0.84–3.29]) (Figure 3). The results from 
multiple sensitivity analyses were justifiably robust to the 
main analysis (Table S7.2 in Supplement 7).
Safety outcomes
We limited this analysis to the three CPAs (HDASA, LDASA, 
and VLDASA) with evidence of efficacy in reducing either 
long-term CRC incidence or mortality (Supplement 8). 
Results from NMA showed that HDASA ranked the lowest 
for safety (ie, major GI bleeding events) (RR, 4.04 [95% 
CI 1.86–8.76]), followed by LDASA (RR, 1.85 [95% CI 
1.22–2.81]) and VLDASA (RR, 1.44 [95% CI 1.15–1.81]). 
For CV mortality, there was no significant effect demon-
strated by any doses of aspirin within approximately 1–10 
years of initiation.
Network consistency and small study 
effects
The test of global inconsistency showed no inconsistency 
for any outcomes (Supplement 9). Comparison-adjusted 
plots showed no substantial evidence of small study effects, 
although the number of studies included in each comparison 
was small (Supplement 10).
GRADE summary of the evidence
Overall, the quality of evidence based on GRADE is gener-
ally rated as very-low to moderate. Detailed information on 
GRADE summary of evidence is presented in Supplement 11.
Net clinical benefit analysis
All 3 doses of aspirin were significantly better than placebo 
(Table S12.1 in Supplement 12). LDASA provided the highest 
net survival gain (%) of 1.736 (95% CI 1.010–2.434) followed 
by VLDASA (1.091 [95% CI 0.614–1.573] and HDASA 
0.908 [95% CI 0.416–1.342], respectively). LDASA, 
VLDASA, and HDASA would result in a NCB of around 
17, 11, and 9 deaths saved per 1,000 patients treated. The 
scatter plot (Figure 4) of combined risk estimates of CRC, 
CV mortality, and major GI bleeding reveals that LDASA 
has 0.7% less death compared to VLDASA with additional 
0.1% increase in GI bleeding events (Tables S12.1, S12.2 
and Method S12.1 in Supplement 12). The number needed to 
treat (NNT) and number needed to harm (NNH) for LDASA 
is 143 and 1,000, respectively.
For the sensitivity analysis, the NCB of aspirin declines 
when the weighting factor for GI bleeding increases (varying 
from 0.01 to 0.16) (Figure S12.1 in Supplement 12). For the 
threshold analysis, when the case-fatality ratio of GI bleeding 
(weight) increases at 1.0, NCB of LDASA is still better than 
the NCB of VLDASA (Figure S12.2 in Supplement 12). The 
incidences of GI bleeding need to be as high as 25%, (80 
times higher risk of GI bleeding than normal), to demonstrate 
an equivalent NCB for LDASA and VLDASA (Figure S12.3 
in Supplement 12).
Discussion
To the best of our knowledge, this is the first systematic 
review and network meta-analysis in the field of primary 
prevention of CRC by CPAs. The present review, combining 
direct and indirect evidence from 26 RCTs (297,476 partici-
pants) reporting either the early or long-term risk of CRC 
incidence or mortality, is the largest analysis in this field. 
Moreover, we were able to incorporate data of 4 trials for 
early risk of CRC incidence that were previously not analyzed 
(Table S2.2 in Supplement 2) and the DTIA trial (a trial test-
ing different doses of aspirin without control),64 which was 
not included in the pairwise meta-analysis of earlier studies 
reporting the long-term risk of CRC mortality.27,34,37 Based 
on this comprehensive dataset and the use of NMA, we were 
able to conclude that, aspirin, antioxidants, calcium (with or 
without vitamin D), vitamin B6/12 and folic acid, either alone 
or in combination did not have appreciable protective effects 
against CRC within approximately 10 years of initiation. 
Additionally, our analysis suggests that aspirin at the dose 
range of 75–325 mg is a safe and effective intervention to 
reduce long-term CRC mortality and the benefit outweighs 
the risk of bleeding.
For antioxidants, various trials (Table S3.11 in Supple-
ment 3) along with recent meta-analyses have failed to detect 
any protective effects despite supportive evidence from in 
vitro, in vivo, and observational studies.66 It is important 
to note however that most antioxidants trials are relatively 
short in duration and therefore make it difficult to detect any 
appreciable effects that require long-term follow-up. In addi-
tion, antioxidants are a diverse group of compounds. Readers 
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Table 1 Brief description of included studies in network meta-analysis
Author, year (reference) Study 
name 
Study design (double 
blind, placebo controlled, 
randomized trial) 
Population Number of 
participants 
Mean age 
(years) 
Male % Interventions Mean intended 
treatment 
duration (years) 
Mean follow-
up (years) 
Outcome measures 
Randomized controlled trials reported early risk of colorectal cancer incidence 
Gann et al (1993)/ Hennekens  
et al (1996)2,3 
PHSa Yes, 2×2 factorial Male physicians 22,071 53 100 ASA-LD; AOs; PLB 5 (ASA-LD); 12 
(AO) 
5 (ASA-LD); 12 
(AO) 
CV events, cancers and overall mortality 
Peto et al (1988)24,26 BDAT Open control, parallel Male physicians 5,139 62 100 ASA-HD; CTL 6 Up to 9 yearsb CV events and mortality from CV causes 
Farrell et al (1991)25,26 UK-TIA Yes, parallel, 3-arms History of TIA or minor ischemic stroke 2,449 60 73 ASA-LD; ASA-HD; PLB 4.4c (1–7 years) Up to 9 yearsb CV events, mortality from vascular and non-vascular 
causes 
Omenn et al (1996)4 CARET Yes, parallel Cigarette smokers, former smokers, and 
workers exposed to asbestos 
18,314 57 66 AOs; PLB 4 4 Lung cancer, other cancers and overall mortality 
HPS group (2002)5 HPS Yes, 2×2 factorial History of coronary and other occlusive 
arterial disease or diabetes 
20,536 40–80b 75 AOs; PLB 5 5 Major coronary events, cancers and overall mortality 
Duffield-Lillico et al (2002)6 NPCT Yes, parallel History of non-melanoma skin cancer 1,312 63 75 AOs; PLB 4.5 7.4 Non-melanoma skin cancer, other cancers and 
overall mortality 
Virtamo et al (2003)7,8 ATBC Yes, 2×2 factorial Male cigarette smokers 29,133 57 100 AOs; PLB 6.1 6.1 Lung cancer, other cancers and overall mortality 
Trivedi et al (2003)9 NA Yes, parallel Physicians and the general practice population 2,686 75 76 VD; PLB 5 5 Fractures, cancers, CV events and overall mortality 
Zhu et al (2003)13 NA Unclear, parallel-4 arms History of atrophic gastritis 216 56 63 FA+B12; AOs; PLB 2 6 Stomach cancer and other GI cancers 
Hercberg et al (2004)10 SU.VI.MAX Yes, parallel General population 13,017 49 39 AOs; PLB 7.5 7.5 CV events, cancers and overall mortality 
Lonn et al (2005)/ Lonn et al 
(2006)11,12 
HOPEa Yes, 2×2 factorial History of CV diseases or diabetes 9,541 66 73 AOs; FA+B6+B12; PLB 4.5 4.5 Cancer incidence, cancer deaths, major CV events 
and overall mortality 
Cook et al (2005)19 WHSa Yes, 2×2 factorial Female health professionals 39,876 55 0 ASA-VLD; AOs; ASA-
VLD+AOs; PLB 
10.1 10.1 Cancer or CV events 
Wactawski-Wende et al (2006)15 WHI Yes, parallel Postmenopausal women 36,282 59 0 CA+VD; PLB 7 7 Fractures and cancers 
Lappe et al (2007)16 NA Yes, parallel, 3-arms Postmenopausal women 1,179 67 0 CA; CA+VD; PLB 4 4 Fractures and cancers 
Lin et al (2009)17 WACSa Yes, 2×2×2×2 factorial Female health professionals at high risk of CV 
disease 
2,729d 60 0 AOs; PLB 8d 8d CV events, cancers and overall mortality 
Zhang et al (2008)18 WAFACSa Yes, 2×2×2×2 factorial Female health professionals at high risk of CV 
disease 
5,442d 63 0 AOs; FAVB; FAVB+ AOs; 
PLB 
6.8d 6.8d CV events, cancers and overall mortality 
Lippman et al (2009)20 SELECT Yes, 2×2 factorial General population (men only) 35,533 62-6c 100 AOs; PLB 5.5 5.5 Prostate cancer and other cancers 
Gaziano et al (2009)21 PHS II Yes, 2×2×2×2 factorial Male physicians 14,520d 64 100 AOs; PLB 8 8 CV diseases, prostate and total cancer 
Armitage et al (2010)22 SEARCH Yes, 2×2 factorial History of MI 12,064 64 83 FA+B12; PLB 6.7 6.7 CV events and cancers 
Hankey et al (2012)23 VITATOPS Yes, parallel History of recent stroke or transient ischemic 
attack 
8,164 62 64 FAVB; PLB 3.4 3.4 CV events, cancers and overall mortality 
Gao et al (2013)32 NA Open-control, parallel General population 860 61 50 FA;CTL 3 3 Colorectal adenomas 
Randomized controlled trials reported the long-term risk of either colorectal cancer incidence or mortality 
Peto et al (1988)24,27 BDAT Open control, parallel Male physicians 5,139 62 100 ASA-HD; CTL 6 (at least 5 years 
for all patients) 
up to 23a CV events and mortality from CV causes 
Farrell et al (1991)25,27 UK-TIA Yes, parallel, 3-arms History of TIA or minor ischemic stroke 2,449 60 73 ASA-LD; ASA-HD; PLB 4.4c (1–7 years) up to 21–27 a CV events, mortality from vascular and non-vascular 
causes 
Stürmer et al (1998)59 PHSa Yes, 2×2 factorial Male physicians 22,071 53 100 ASA-LD; PLB 5 12 MI and other CV events; cancer 
Virtamo et al (2003)8 ATBC Yes, 2×2 factorial Male cigarette smokers 29,133 57.2 100 AOs; PLB 6.1 12 Cancer incidence and mortality 
Goodman et al (2004)28 CARET Yes, parallel Cigarette smokers, former smokers, and 
workers exposed to asbestos 
18,314 57 66 AOs; PLB 4 10 Lung cancer and other cancers 
Ebbing et al (2009)29,60,61 NORVIT/ 
WENBITa
Yes, Combined analysis and 
extended follow-up of 2 RCTs.
History of ischemic heart disease 6,837 (both 
trials) 
62 76 FAVB; FA+B12; PLB 3.2 6.4 CV outcomes 
Cook et al (2013)30 WHS Yes, 2×2 factorial Female health professionals 39,876 55 0 ASA-VLD; CTL 10.1 18 Any invasive cancer 
Cauley et al (2013)31 WHI Yes, parallel Postmenopausal women 36,282 59 0 CA+VD; PLB 7 11 Fractures and colorectal cancer 
Rothwell et al (2010)27 TPT62 Yes, 2×2 factorial High risk for IHD 5,085 57.5 100 ASA-VLD; PLB 7 (at least 5 years) Up to 17–20b Ischemic heart diseases 
SALT63 Yes, parallel History of TIA or stroke 1,360 70 66 ASA-VLD; PLB 2.7 (1–5 years) Up to 18–23b Composite outcome of stroke or death from any causes 
DTIA64 No placebo, parallel History of TIA or stroke 3,131 65.3 65 ASA-VLD; ASA-LD 2.6 (1–4 years) Up to 17b Death from CV causes 
Notes: A more detailed description with efficacy outcomes from all individual studies is reported in Supplement 3. WHS and PHS are alternate-day dose studies (100 mg every 
other day (defined as ASA-VLD) and 325 mg every other day (ASA-LD), respectively).34 aDetailed description of studies provided in Table S2.2 in Supplement 2. bRange. cMedian. 
dBased on data provided by authors (refer Tables S2.1 and S2.2 in Supplement 2). eLong-term data of these trials extracted from an IPD meta-analysis reported by Rothwell 2010.27
Abbreviations: ASA, asprin; AO, antioxidant; ATBC, Alpha-Tocopherol, Beta-Carotene Cancer Prevention study; B6, vitamin B6; B12, vitamin B12; BDAT, British 
Doctors Aspirin Trial; CA, calcium; CARET, carotene and retinol efficacy trial; CTL, control; CV, cardiovascular; DTIA, Dutch Transient Ischaemic Attack Trial; FA, folic 
acid; FAVB, folic acid with vitamin B6 and B12; GI, gastrointestinal; HD, high-dose; HOPE, Heart Outcomes Prevention Evaluation trial; HPS, Heart Protection Study; 
IHD, ischemic heart disease; LD, low-dose; MI, myocardial infarction; NPCT, nutritional prevention of cancer trial; NORVIT, Norwegian Vitamin Trial; PHS, Physicians’ 
Health Study; PLB, placebo; SALT, Swedish Aspirin Low Dose Trial; SEARCH, Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine; 
SELECT, Selenium and Vitamin E Cancer Prevention Trial; SU.VI.MAX, Supplémentation en Vitamines et Minéraux Antioxydants study; TPT, Thrombosis Prevention Trial; 
TIA, transient ischemic attack; UK-TIA, UK Transient Ischaemic Attack Aspirin Trial; VD, vitamin D, VITATOPS, Vitamins to Prevent Stroke Trial; VLD, very-low-dose; 
WACS, The Women’s Antioxidant Cardiovascular Study; WAFACS, Women’s Antioxidant and Folic Acid Cardiovascular Study; WENBIT, Western Norway B Vitamin 
Intervention Trial; WHI, women’s health initiative; WHS, Women’s Health Study.
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Table 1 Brief description of included studies in network meta-analysis
Author, year (reference) Study 
name 
Study design (double 
blind, placebo controlled, 
randomized trial) 
Population Number of 
participants 
Mean age 
(years) 
Male % Interventions Mean intended 
treatment 
duration (years) 
Mean follow-
up (years) 
Outcome measures 
Randomized controlled trials reported early risk of colorectal cancer incidence 
Gann et al (1993)/ Hennekens  
et al (1996)2,3 
PHSa Yes, 2×2 factorial Male physicians 22,071 53 100 ASA-LD; AOs; PLB 5 (ASA-LD); 12 
(AO) 
5 (ASA-LD); 12 
(AO) 
CV events, cancers and overall mortality 
Peto et al (1988)24,26 BDAT Open control, parallel Male physicians 5,139 62 100 ASA-HD; CTL 6 Up to 9 yearsb CV events and mortality from CV causes 
Farrell et al (1991)25,26 UK-TIA Yes, parallel, 3-arms History of TIA or minor ischemic stroke 2,449 60 73 ASA-LD; ASA-HD; PLB 4.4c (1–7 years) Up to 9 yearsb CV events, mortality from vascular and non-vascular 
causes 
Omenn et al (1996)4 CARET Yes, parallel Cigarette smokers, former smokers, and 
workers exposed to asbestos 
18,314 57 66 AOs; PLB 4 4 Lung cancer, other cancers and overall mortality 
HPS group (2002)5 HPS Yes, 2×2 factorial History of coronary and other occlusive 
arterial disease or diabetes 
20,536 40–80b 75 AOs; PLB 5 5 Major coronary events, cancers and overall mortality 
Duffield-Lillico et al (2002)6 NPCT Yes, parallel History of non-melanoma skin cancer 1,312 63 75 AOs; PLB 4.5 7.4 Non-melanoma skin cancer, other cancers and 
overall mortality 
Virtamo et al (2003)7,8 ATBC Yes, 2×2 factorial Male cigarette smokers 29,133 57 100 AOs; PLB 6.1 6.1 Lung cancer, other cancers and overall mortality 
Trivedi et al (2003)9 NA Yes, parallel Physicians and the general practice population 2,686 75 76 VD; PLB 5 5 Fractures, cancers, CV events and overall mortality 
Zhu et al (2003)13 NA Unclear, parallel-4 arms History of atrophic gastritis 216 56 63 FA+B12; AOs; PLB 2 6 Stomach cancer and other GI cancers 
Hercberg et al (2004)10 SU.VI.MAX Yes, parallel General population 13,017 49 39 AOs; PLB 7.5 7.5 CV events, cancers and overall mortality 
Lonn et al (2005)/ Lonn et al 
(2006)11,12 
HOPEa Yes, 2×2 factorial History of CV diseases or diabetes 9,541 66 73 AOs; FA+B6+B12; PLB 4.5 4.5 Cancer incidence, cancer deaths, major CV events 
and overall mortality 
Cook et al (2005)19 WHSa Yes, 2×2 factorial Female health professionals 39,876 55 0 ASA-VLD; AOs; ASA-
VLD+AOs; PLB 
10.1 10.1 Cancer or CV events 
Wactawski-Wende et al (2006)15 WHI Yes, parallel Postmenopausal women 36,282 59 0 CA+VD; PLB 7 7 Fractures and cancers 
Lappe et al (2007)16 NA Yes, parallel, 3-arms Postmenopausal women 1,179 67 0 CA; CA+VD; PLB 4 4 Fractures and cancers 
Lin et al (2009)17 WACSa Yes, 2×2×2×2 factorial Female health professionals at high risk of CV 
disease 
2,729d 60 0 AOs; PLB 8d 8d CV events, cancers and overall mortality 
Zhang et al (2008)18 WAFACSa Yes, 2×2×2×2 factorial Female health professionals at high risk of CV 
disease 
5,442d 63 0 AOs; FAVB; FAVB+ AOs; 
PLB 
6.8d 6.8d CV events, cancers and overall mortality 
Lippman et al (2009)20 SELECT Yes, 2×2 factorial General population (men only) 35,533 62-6c 100 AOs; PLB 5.5 5.5 Prostate cancer and other cancers 
Gaziano et al (2009)21 PHS II Yes, 2×2×2×2 factorial Male physicians 14,520d 64 100 AOs; PLB 8 8 CV diseases, prostate and total cancer 
Armitage et al (2010)22 SEARCH Yes, 2×2 factorial History of MI 12,064 64 83 FA+B12; PLB 6.7 6.7 CV events and cancers 
Hankey et al (2012)23 VITATOPS Yes, parallel History of recent stroke or transient ischemic 
attack 
8,164 62 64 FAVB; PLB 3.4 3.4 CV events, cancers and overall mortality 
Gao et al (2013)32 NA Open-control, parallel General population 860 61 50 FA;CTL 3 3 Colorectal adenomas 
Randomized controlled trials reported the long-term risk of either colorectal cancer incidence or mortality 
Peto et al (1988)24,27 BDAT Open control, parallel Male physicians 5,139 62 100 ASA-HD; CTL 6 (at least 5 years 
for all patients) 
up to 23a CV events and mortality from CV causes 
Farrell et al (1991)25,27 UK-TIA Yes, parallel, 3-arms History of TIA or minor ischemic stroke 2,449 60 73 ASA-LD; ASA-HD; PLB 4.4c (1–7 years) up to 21–27 a CV events, mortality from vascular and non-vascular 
causes 
Stürmer et al (1998)59 PHSa Yes, 2×2 factorial Male physicians 22,071 53 100 ASA-LD; PLB 5 12 MI and other CV events; cancer 
Virtamo et al (2003)8 ATBC Yes, 2×2 factorial Male cigarette smokers 29,133 57.2 100 AOs; PLB 6.1 12 Cancer incidence and mortality 
Goodman et al (2004)28 CARET Yes, parallel Cigarette smokers, former smokers, and 
workers exposed to asbestos 
18,314 57 66 AOs; PLB 4 10 Lung cancer and other cancers 
Ebbing et al (2009)29,60,61 NORVIT/ 
WENBITa
Yes, Combined analysis and 
extended follow-up of 2 RCTs.
History of ischemic heart disease 6,837 (both 
trials) 
62 76 FAVB; FA+B12; PLB 3.2 6.4 CV outcomes 
Cook et al (2013)30 WHS Yes, 2×2 factorial Female health professionals 39,876 55 0 ASA-VLD; CTL 10.1 18 Any invasive cancer 
Cauley et al (2013)31 WHI Yes, parallel Postmenopausal women 36,282 59 0 CA+VD; PLB 7 11 Fractures and colorectal cancer 
Rothwell et al (2010)27 TPT62 Yes, 2×2 factorial High risk for IHD 5,085 57.5 100 ASA-VLD; PLB 7 (at least 5 years) Up to 17–20b Ischemic heart diseases 
SALT63 Yes, parallel History of TIA or stroke 1,360 70 66 ASA-VLD; PLB 2.7 (1–5 years) Up to 18–23b Composite outcome of stroke or death from any causes 
DTIA64 No placebo, parallel History of TIA or stroke 3,131 65.3 65 ASA-VLD; ASA-LD 2.6 (1–4 years) Up to 17b Death from CV causes 
Notes: A more detailed description with efficacy outcomes from all individual studies is reported in Supplement 3. WHS and PHS are alternate-day dose studies (100 mg every 
other day (defined as ASA-VLD) and 325 mg every other day (ASA-LD), respectively).34 aDetailed description of studies provided in Table S2.2 in Supplement 2. bRange. cMedian. 
dBased on data provided by authors (refer Tables S2.1 and S2.2 in Supplement 2). eLong-term data of these trials extracted from an IPD meta-analysis reported by Rothwell 2010.27
Abbreviations: ASA, asprin; AO, antioxidant; ATBC, Alpha-Tocopherol, Beta-Carotene Cancer Prevention study; B6, vitamin B6; B12, vitamin B12; BDAT, British 
Doctors Aspirin Trial; CA, calcium; CARET, carotene and retinol efficacy trial; CTL, control; CV, cardiovascular; DTIA, Dutch Transient Ischaemic Attack Trial; FA, folic 
acid; FAVB, folic acid with vitamin B6 and B12; GI, gastrointestinal; HD, high-dose; HOPE, Heart Outcomes Prevention Evaluation trial; HPS, Heart Protection Study; 
IHD, ischemic heart disease; LD, low-dose; MI, myocardial infarction; NPCT, nutritional prevention of cancer trial; NORVIT, Norwegian Vitamin Trial; PHS, Physicians’ 
Health Study; PLB, placebo; SALT, Swedish Aspirin Low Dose Trial; SEARCH, Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine; 
SELECT, Selenium and Vitamin E Cancer Prevention Trial; SU.VI.MAX, Supplémentation en Vitamines et Minéraux Antioxydants study; TPT, Thrombosis Prevention Trial; 
TIA, transient ischemic attack; UK-TIA, UK Transient Ischaemic Attack Aspirin Trial; VD, vitamin D, VITATOPS, Vitamins to Prevent Stroke Trial; VLD, very-low-dose; 
WACS, The Women’s Antioxidant Cardiovascular Study; WAFACS, Women’s Antioxidant and Folic Acid Cardiovascular Study; WENBIT, Western Norway B Vitamin 
Intervention Trial; WHI, women’s health initiative; WHS, Women’s Health Study.
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must, therefore, note that the findings of our analysis only 
applied to beta-carotene, vitamin A, vitamin E, vitamin C, 
selenium, and zinc.
Observational studies suggested a relationship among cal-
cium and vitamin D levels and CRC.67,68 A recent meta-analysis 
suggested that calcium may have a moderate  protective effect 
on CRC recurrence.69 However, we did not find any effects 
of calcium (alone or with vitamin D). A recent phase-2 trial 
showed that high-dose vitamin D3 (loading dose of 8,000 IU/
day orally for 2 weeks followed by 4,000 IU/day) significantly 
improved survival in patients with metastatic CRC.70 It should 
be noted that low dose (400 IU/day) of vitamin D was used in 
Figure 1 Network plot of chemopreventive agents tested in RCTs for early risk of CRC incidence.
Abbreviations: RCT, randomized controlled trials; CRC, colorectal cancer; ASA, asprin; HD, high-dose; LD, low-dose; VLD, very-low-dose; VitaminB12; B6, vitamin B6; 
CA, calcium; AO, antioxidants; FA, folic acid; VD, vitamin D.
ASA-VLF+AO
ASA-VLD
VD
FA
ASA-LD
CA
CA+VD
ASA-HD
PlaceboFA+B12+B6+AO
FA+B12+B6
FA+B12
AO
Figure 2 Network plots of chemopreventive agents tested in RCTS (follow-up 0–≥20 years) for (A) long-term risk of CRC incidence (B) long-term risk of CRC mortality. 
Abbreviations: RCT, randomized controlled trials; CRC, colorectal cancer; ASA, asprin; HD, high-dose; LD, low-dose; VLD, very-low-dose; VitaminB12; B6, vitamin B6; 
CA, calcium; AO, antioxidants; FA, folic acid; VD, vitamin D.
ASA-HD ASA-HD
ASA-LD
A B
ASA-LD
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all primary prevention trials (and not in the form of vitamin 
D3).69,71 As a result, future trials of vitamin D may need to 
explore both different forms and various dosing of vitamin D.
Previous studies of folic acid supplementation on CRC 
showed inconsistent results.40,72,73 We did not find either a 
decrease or an increase in the risk of CRC in any folic interven-
tion (Table S3.12 in Supplement 3). A recent study suggested 
that the effect of folic acid may depend upon the existing level 
of blood folate along with methylenetetrahydrofolate reductase 
(MTHFR) genotype.74 Therefore, the effect of folic acid on 
CRC may require further investigation based on those factors.
Over the past few decades, data concerning aspirin 
derived from RCTs and meta-analyses generated mostly 
discouraging findings for CRC prevention after medium-
term, in-trial follow-up (≤10 years).2,19,36,37 However, recent 
extended follow-up of RCTs has shown remarkably consis-
tent evidence on the protective effect of aspirin against long-
term CRC incidence and mortality.27,30,34 The 2016 USPSTF 
guideline35,75 suggested the use of aspirin (<100 mg/day) for 
primary CRC prevention in people who have a 10% or greater 
10-year risk for CVD and who are not at an increased risk of 
bleeding. This recommendation was derived from pairwise 
meta-analysis and multi-criteria decision analysis (MCDA) 
using a microsimulation model to systematically estimate 
the balance of benefits and harms through the gain in net 
life years and quality-adjusted life years.34,50 Our analysis 
took different approaches. First, we explored the compara-
tive efficacy of different CPAs including aspirin to ensure 
that all interventions in the landscape were represented and 
analyzed.27,34,36–40 Our results lend strong support to USPSTF 
by showing that, based on the most current data, aspirin is 
the only effective CPA compared to placebo and other CPAs.
While USPSTF analysis attempted to evaluate the effect 
of doses and duration of treatment, no meaningful analysis 
was made due to the limited amount of direct head-to-head 
trials of different doses of aspirin. To extend beyond USPSTF 
analysis, we did an NMA to comprehensively compare 3 doses 
of aspirin and able to show detailed differences in efficacy 
and safety of aspirin at different doses (Figure 3). We believe 
that this analysis is useful since aspirin demonstrated a dose-
dependent effect relating to the risks of GI bleeding events 
and hemorrhagic stroke.76 Therefore, selection of aspirin dose 
for long-term use requires striking the right balance between 
benefit and risk. To tackle this issue, we used NCB to simulta-
neously evaluate  effects of aspirin on CRC and CV mortality 
along with major GI bleeding of different aspirin doses. Based 
on this comprehensive evaluation investigating the multidi-
mensional effects of aspirin, we were able to show that both 
LDASA and VLDASA appeared to strike an optimal balance 
on CV and CRC mortality vs major GI bleeding (Figure 4). 
Based on analysis with different weighting on major GI bleed-
ing event, LDASA seemed to provide the highest net survival 
gain among different doses of aspirin. However, we caution 
readers that this result is far from definite and should be taken 
as hypothesis generated for further research to try to identify 
the optimal dose of aspirin for CRC prevention, cardiovas-
cular disease prevention along with acceptable adverse drug 
reaction. As a result, until more evidence becomes available, 
it may be prudent to consider both low-dose (100–325 mg/
day) and very-low-dose aspirin (75–100 mg/day) as the viable 
options for both CRC and cardiovascular disease prevention.
Limitations of study
Our study has several important limitations. First, most data 
on long-term CRC incidence and mortality were collected 
post hoc as a part of follow-up trials that included other out-
comes as predefined endpoints, rather than CRC incidence 
or mortality. The completeness in capturing those events may 
be questionable. Second, differences in patient population, 
trial conducts, and trial methodology across studies may 
Figure 3 Efficacy and safety of aspirin for colorectal cancer in network meta-analysis.
Notes: Efficacy outcomes are long-term CRC incidence and CRC mortality. Safety outcomes are major GI bleeding events and CV deaths. Risk ratio (95% credible interval) 
of comparisons for each outcome is in cells in common between column-defining and row-defining treatment. Comparison between treatments should read from row to 
column for CRC event and CV mortality and column to row for CRC mortality and major GI bleeding events. For risk of CRC event and CV mortality, risk ratio <1 favor 
row-defining treatment. For risk of CRC mortality and GI bleeding events, risk ratio, <1 favor column-defining treatment. Orange shaded results indicate statistical significance.
Abbreviations: CRC, colorectal cancer; CV, cardiovascular; GI, gastrointestinal; ASA, asprin; HD, high-dose; LD, low-dose; VLD, very-low-dose; PCB, placebo.
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(0.77, 1.02)
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(0.82, 1.03)
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create an inherent heterogeneity especially the difference in 
treatment duration and follow-up period. Third, our analysis 
on the effects of aspirin doses can be perceived as hypothesis 
generation since data are still too limited to make a definitive 
conclusion on the dose-specific effects of aspirin. However, 
we still believe that aspirin at the dose of 75–325 mg/day 
is best supported by not only our study but also previous 
reports. Until new large RCTs comparing different doses 
of aspirin are available, we believe that our findings offer 
a range of aspirin dose for clinician and patient to discuss 
and make a shared decision to choose what dose of aspirin 
may suit the differential risk-benefit profile of each patient. 
While recognizing the impact of age on the risk-benefit of 
aspirin, we were unable to perform detailed analysis based 
on age due to the lack of individual patient data. Based on 
this limitation along with the definite incremental risk of 
aspirin with advanced age and lack of robust data to sup-
port efficacy for long-term CRC prevention in the elderly, 
we caution the readers to avoid extrapolating these results 
toward elderly patients.
Conclusions and policy implications
Our analysis suggests that aspirin was the only interven-
tion that showed protective effects with potential dose-
dependent effects while none of the other CPAs was found 
to be effective. Aspirin at the dose range of 75–325 mg/day 
is a safe and effective primary prevention for long-term 
CRC among people at average risk. For patients with low 
risk of bleeding, low-dose aspirin (>100–325 mg/day) 
may slightly be more attractive due to a larger reduction 
in CRC mortality and the best net clinical benefit. For 
patients at high risk of bleeding, very-low-dose aspirin 
(<100 mg/day) might be appropriate due to its best safety 
profile especially GI bleeding. There may potentially be 
differential effects among various doses of aspirin that 
needs further investigation.
Data sharing
Technical appendix and dataset available from the corre-
sponding authors.
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